Cell Viability Score as an Integrated Indicator for Cytotoxicity of Benzalkonium Chloride-Containing Antiglaucoma Eyedrops

DOI PubMed 48 References Open Access
  • AYAKI MASAHIKO
    Department of Ophthalmology, Mita Hospital, International University of Health and Welfare
  • IWASAWA ATSUO
    Department of Bioengineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology
  • NIWANO YOSHIMI
    Laboratory for Redox Regulation, Tohoku University Graduate School of Dentistry

Search this article

Description

We evaluated the in vitro cytotoxicity of benzalkonium chloride (BAK) -containing antiglaucoma eyedrops. We prepared cell cultures of SIRC, BCE C/D-1b, RC-1, and Chang conjunctiva. The viability of cell cultures was determined using the MTT and neutral red assays. The cell viability score (CVS) was used to compare the toxicity of test solutions. %CVS50 and %CVS40/80 of each eyedrop solution were 71 and 26 for Lumigan® (0.002% bimatoprost with 0.005% BAK) , 100 and 99 for Tapros® (0.0015% tafluprost, a new formula from 2010 with 0.001% BAK) , 39 and -29 for 2% Trusopt® (2% dorzolamide with 0.0075% BAK) , 28 and -43 for Xalacom® (latanoprost/0.5% timolol with 0.02% BAK) , 88 and 66 for DuoTrav® (travoprost/0.5% timolol with no BAK) , 36 and -35 for Cosopt® (2% dorzolamide/0.5% timolol with 0.0075% BAK) and 53 and -1 for Combigan® (0.15% brimonidin/0.5% timolol with 0.005% BAK) . Only Xalacom® and Tapros® did not show an apparent decrease in %CVS as compared to the corresponding concentration of BAK. In conclusion, the cytotoxicity of tested eyedrops was dependent on BAK. Only the eyedrops containing latanoprost or tafluprost showed a reduction in the cytotoxicity of BAK.

Journal

  • Biocontrol Science

    Biocontrol Science 17 (3), 121-128, 2012

    The Society for Antibacterial and Antifungal Agents, Japan

References(48)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top